Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Japan Rare Disease Treatment Market Segmentation
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1.Executive Summary
2. Japan Rare Disease Treatment Market Introduction
2.1. Japan Rare Disease Treatment Market - Taxonomy
2.2. Japan Rare Disease Treatment Market - Definitions
2.2.1.By Molecule/Product
2.2.2.By Disease
3. Japan Rare Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
4. Japan Rare Disease Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Japan Rare Disease Treatment Market By Molecule/Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Selumetinib
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Eculizumab
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Asfostatse Alfa
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Ravulizumab-cwvz
5.4.1.Ravulizumab-cwvz Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Velaglucerase alfa
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Imiglucerase
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Elosulfase alfa
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Agalsidase Beta BS
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. lanadelumab
5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
5.10. ADYNOVATE
5.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.10.3. Market Opportunity Analysis
5.11. Others
5.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.11.3. Market Opportunity Analysis
6. Japan Rare Disease Treatment Market By Disease, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hemophilia
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Gaucher Disease
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Morquio Syndrome
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Fabry disease
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Atypical Hemolytic Uremic Syndrome
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Lysosomal Acid Lipase De?ciency
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Neurofibromatosis Type 1 Plexiform Neurofibromas
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Neuromyelitis Optica Spectrum Disorder
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Paroxysmal Nocturnal Hemoglobinuria
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Hereditary Angioedema (HAE)
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Others
6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
7. Competition Landscape
7.1. Market Player Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
7.2.1.Biogen Japan Ltd.
7.2.2.Alexion Pharma G.K.
7.2.3.Sanofi
7.2.4.Fujifilm
7.2.5.Takeda Pharmaceutical
7.2.6.Astellas
7.2.7.Insmed G.K
7.2.8.Alnylam Japan K.K.
7.2.9.Novartis
7.2.10.JCR Pharmaceutical
7.2.11.Biomarin Pharmaceutical Japan K.K.
8. Research Methodology
9. Appendix and Abbrevations
2. Japan Rare Disease Treatment Market Introduction
2.1. Japan Rare Disease Treatment Market - Taxonomy
2.2. Japan Rare Disease Treatment Market - Definitions
2.2.1.By Molecule/Product
2.2.2.By Disease
3. Japan Rare Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
4. Japan Rare Disease Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Japan Rare Disease Treatment Market By Molecule/Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Selumetinib
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Eculizumab
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Asfostatse Alfa
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Ravulizumab-cwvz
5.4.1.Ravulizumab-cwvz Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Velaglucerase alfa
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Imiglucerase
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Elosulfase alfa
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Agalsidase Beta BS
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. lanadelumab
5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
5.10. ADYNOVATE
5.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.10.3. Market Opportunity Analysis
5.11. Others
5.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.11.3. Market Opportunity Analysis
6. Japan Rare Disease Treatment Market By Disease, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hemophilia
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Gaucher Disease
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Morquio Syndrome
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Fabry disease
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Atypical Hemolytic Uremic Syndrome
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Lysosomal Acid Lipase De?ciency
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Neurofibromatosis Type 1 Plexiform Neurofibromas
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Neuromyelitis Optica Spectrum Disorder
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Paroxysmal Nocturnal Hemoglobinuria
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Hereditary Angioedema (HAE)
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Others
6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
7. Competition Landscape
7.1. Market Player Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
7.2.1.Biogen Japan Ltd.
7.2.2.Alexion Pharma G.K.
7.2.3.Sanofi
7.2.4.Fujifilm
7.2.5.Takeda Pharmaceutical
7.2.6.Astellas
7.2.7.Insmed G.K
7.2.8.Alnylam Japan K.K.
7.2.9.Novartis
7.2.10.JCR Pharmaceutical
7.2.11.Biomarin Pharmaceutical Japan K.K.
8. Research Methodology
9. Appendix and Abbrevations
Biogen Japan Ltd.
Alexion Pharma G.K.
Sanofi
Fujifilm
Takeda Pharmaceutical
Astellas
Insmed G.K
Alnylam Japan K.K.
Novartis
JCR Pharmaceutical
Biomarin Pharmaceutical Japan K.K.
Alexion Pharma G.K.
Sanofi
Fujifilm
Takeda Pharmaceutical
Astellas
Insmed G.K
Alnylam Japan K.K.
Novartis
JCR Pharmaceutical
Biomarin Pharmaceutical Japan K.K.